Psychedelics for Anxiety Disorders – From MDMA to ACT
With a groundbreaking clinical trial investigating MDMA-assisted therapy for Social Anxiety Disorder, clinical psychologist Jason Luoma has been a pioneering figure in exploring how psychedelics might transform our approach to anxiety. But how can psychedelic treatments extend beyond MDMA, and what role might therapies like Acceptance and Commitment Therapy (ACT) play in managing anxiety and avoidance?
The Conversation on the 16th of September
Jason Luoma joins clinical psychologist Filip Bromberg for an engaging discussion on the role of psychedelics in treating anxiety disorders. They will explore Jason's recent MDMA-assisted therapy trial for Social Anxiety Disorder, discuss broader psychedelic research for anxiety, and delve into how ACT provides a valuable psychological framework for understanding and addressing anxiety-related avoidance. How can clinicians integrate psychedelics into their practice responsibly, and what implications does this have for future mental health treatments? Join us for a thought-provoking dialogue about the intersection of psychedelics, anxiety disorders, and therapeutic innovation.
Date & Time: September 16th 19.00 CEST
Registration: https://us06web.zoom.us/webinar/register/WN_XK7sJo8WTIK_mm5pXaK7nw
Deepen Your Learning
Interested in further integrating ACT into your clinical practice with psychedelics? Jason Luoma will also be leading an immersive full-day workshop on September 25th in Stockholm. This workshop offers clinicians a comprehensive, practical exploration of how ACT principles can enrich psychedelic-assisted therapy, from preparation to integration, with an emphasis on clinical applications, ethical practice, and experiential exercises.
Learn more about the workshop here
About Jason Luoma
Dr. Jason Luoma is a clinical psychologist, researcher, and internationally recognized expert in Acceptance and Commitment Therapy (ACT). As co-founder of Portland Psychotherapy Clinic, Research, & Training Center, he has dedicated his career to integrating science and practice, notably leading a pioneering study on MDMA-assisted psychotherapy for Social Anxiety Disorder. Dr. Luoma's work emphasizes compassion, evidence-based practices, and innovative approaches to mental health treatment. He will also be featured as a speaker at the upcoming Borealis Psychedelic Science Summit in Stockholm, September 27–28, 2025.
This webinar is brought to you by Borealis Psychedelic Science Summit, in collaboration with the Swedish Psychedelic Education Company Lavin.